Glaukos Corporation vs Johnson & Johnson — Stock Comparison
Glaukos Corporation (GKOS) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of Glaukos Corporation on Q·Score (7.1 vs 5.9 out of 10), led by Quality (9.3 vs 1.1) and Valuation (7.3 vs 5). Glaukos Corporation scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for GKOS (+20.5%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-34% margin).
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
GKOS vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Glaukos Corporation (GKOS) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: GKOS or JNJ?
Glaukos Corporation (GKOS) scores higher on Growth (7.4/10 vs 5.1/10). Glaukos Corporation reports revenue growth (41.2% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is GKOS or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 5/10). GKOS trades at 294.6× P/E versus JNJ at 18.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about GKOS vs JNJ?
There are 12 analysts covering GKOS with a consensus price target of $157.50, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: GKOS or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 1.1/10). Net profit margin: GKOS at -34.3%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: GKOS or JNJ?
Glaukos Corporation (GKOS) scores higher on Financial Health (9.2/10 vs 6.5/10). Market beta: GKOS at 0.81, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of GKOS and JNJ?
Glaukos Corporation (GKOS) has a market capitalisation of $7.7B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do GKOS or JNJ pay dividends?
GKOS does not currently pay a dividend, while JNJ pays a dividend yield of 2.35%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →